版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
·亓立峰浙江加州國(guó)際納米技術(shù)研究院·前言:納米微粒概述·Part
I:納米藥物與靶向設(shè)計(jì)·Part
II:腫瘤納米分子影像與實(shí)時(shí)治療·Part
III:納米探針·前景展望What
is
Nano?Quantum
dots,
magnetic
NPFig1.
A
schemetic
of
nanoscale
materialPolymer
NPPhycoerythrin前言某種物質(zhì)或元素納米級(jí)別粒子:nano
Zinic;SiO2,nano
gold,CdSe/ZnS,Fe2O3,Polymer
NPDegradablePolymericmatrixnanospherenanocapsuleOily
or
aqueous
corePolymericmembrane前言化學(xué)法:(1)沉淀法/透析法把沉淀劑加入到鹽溶液中反應(yīng)后,(將沉淀熱處理)得到納米材料。其特點(diǎn)簡(jiǎn)單易行,但純度低,顆粒半徑大,聚合體納米粒子、氧化物。(2)微乳液法/乳液擴(kuò)散法兩種互不相溶的溶劑在表面活性劑的作用下形成乳液,在微泡中經(jīng)成核、聚結(jié)、團(tuán)聚、(熱處理)后得納米粒子。其特點(diǎn)粒子的單分散和界面性好,聚合體納米粒子、Ⅱ~Ⅵ族半導(dǎo)體納米粒子多用此法制備納米微粒制備方法前言納米粒子表征方法測(cè)
量
方
法測(cè)量功能適用的尺寸范圍使用的主要儀器離心沉降法等效直徑>25nm高速離心機(jī),分光光度計(jì)或暗場(chǎng)法光學(xué)系統(tǒng)氣體吸附法(容量法或重量法)比表面積尺寸:約1~10nm比表面積:0.1~1000m2/gBET吸附裝置或重量法裝置光散射法平均直徑>約3nm喇曼光譜儀X射線衍射峰寬法晶粒平均尺寸約<500nm常用于<50nmX射線衍射儀小角度X射線散射線晶粒平均尺寸約<100nmX射線衍射儀電子成像法(TEM)直接觀察粒子形貌并測(cè)量粒徑尺寸約>2nm透射電子顯微鏡掃描隧道顯微鏡法(STM)形貌與尺寸寬范圍掃描隧道顯微鏡粒徑分析粒徑分布粒徑分析儀熒光光譜法熒光圖譜熒光光譜儀These
newly
formed
tumor
vessels
areusually
abnormal
in
form
and
architecture.They
are
poorly-aligned
defectiveendothelial
cells
with
wide
fenestrations,lacking
a
smooth
muscle
layer,
orinnervation
with
a
wider
lumen,
andimpaired
functional
receptors
forangiotensin
II.
Furthermore,
tumor
tissues
usually
lack
effective
lymphatic
drainage.All
these
factors
will
lead
to
abnormalmolecular
and
fluid
transport
dynamicsespecially
for
macromolecular
drugs.“enhanced
permeability
and
retention(EPR)-effect”
of
macromolecules
andlipids
in
solid
tumors./wiki/Enhanced_Per
meability_and_Retention_effectEnhanced
permeability
and
retention(EPR)
effect.
Long-circulating
drugcarriers
(1),
penetrate
through
the
leakyNamely,
this
phenomenon
was
coinedpathological
vasculature
(2),
into
thetumor
interstitium
(3),
and
degradethere,
releasing
a
free
drug
(4)
andcreating
its
high
local
concentration.AAPS
Journal.
2007;9(2):Article
15.DOI:10.1208/aapsj0902015Nanoparticles
:
clinicaladministration
of
anticancerdrugs.Advantages:√
Controlled
and
targeteddelivery
of
the
drug√
Reduced
systemic
side
effects√
Facilitated
extravasation
intothe
tumor
cells
(EPR
effect:enhanced
permeability
andretention)√
High
capability
to
crossvarious
physiological
barriersFig.3
Size
and
zeta
potential
of
CNP
and
CNP-CuL.
Qi,
et
al,
Colloids
Surfaces
A:
Physicochem
Eng
Aspects
2004;
251:
183190
;
Carbohydrate
Research
2004;
2693-270050
mV96
mVCNP-Cu13
mVChitosanCNPCNP-CuCNPPanel
of
celllineCell
lineCytotoxicity
(IC50,μg/mL)Chitosan
CNP
CNP-CuLiverL-02na
na
naColon
cancerCalo3201200(±
28(±3)
14(±2)27)Gastric
cancerBGC8231200(±35)
21(±2)
8
(±1)Liver
cancerBEL74021200(±22)
15(±2)
6
(±1)Values
are
means
of
three
experiments,
standard
deviation
is
given
inparenthese=
not
active).L.
Qi,
et
al,
Bioorganic
&
Medicinal
Chemistry
Letters
2005;
15:
1357-1399Table
1.
Cytotoxic
activity
of
chitosan,
CNP
(mean
particle
size
=
40
nm),
andCNP-Cu
against
different
cell
linesFig.5
CNP-induced
changes
of
MMP
and
zeta
potential
of
membrane.
A:
Loss
of
MMPand
zeta
potential;
Histogram
of
untreated
cells
(B)
and
cells
treated
with
100
μg/mL
CNP(C)CNP
could
neutralize
the
negative
surface
charge
of
BEL7402
cells
so
as
todamage
the
cell
membrane.
The
strong
dissipation
in
MMP
suggestsapossible
disruption
of
mitochondrial
membrane
after
treated
with
CNP.L.
Qi,
et
al,
Eur.
J.
Cancer
2007;
43:184-93Fatty
acidControl
(μg/mg)CNP
group
(μg/mg)C14:029.93±2.0130.29±2.21C16:0216.5±13.73215.51±5.41C18:0255.61±14.86252.11±10.99C18:1142.62±8.52108.66±5.11aC18:2226.22±8.29195.78±4.54
aC20:412.97±1.469.87±0.45
aaP<0.01
vs
ControlTable
2
Effects
of
CNP
on
fatty
acid
composition
ofmembrane
phosphoric
lipid
from
BEL7402
cellsFig.
6
Lipid
peroxidation
measured
asthiobarbituric
acid
reactive
substances(TBARs)
production
of
BEL7402
cells
non-treated
or
treated
for
24
h
with
variousdoses
of
CNP.Increased
ROS
(Reactive
oxygen
species)production
and
LPO
degree,
decreasedunsaturated
fattyacid
indicatedthat
CNPexerted
membrane
penetration
activity
byinductionof
LPOGroupsBWincrease
(g)TW
(g)TIR
(%)Control1.54±0.562.95±0.46-Chitosan1.78±0.972.24±0.41b2440
nm
CNP2.40±0.441.13±0.22b6270
nm
CNP2.38±0.481.21±0.29b59100
nm
CNP1.96±0.851.92±0.46b35Cisplatin
-2.3±0.99
0.56±0.13bSide
effects
of
chemotherapy81Table
4
Effect
of
CNP
with
different
particle
sizeon
BEL7402
tumor
cell
growth
in
nude
mice
byoral
administration
(1
mg/kg/day)Fig.
7
Effects
ofadministration
routes
onantitumor
efficacy
of
CNPagainstSarcoma-180
subcutaneous
tumorformation
and
growth
in
ICR
mice
Imaging:
cancer
diagnostics,
staging,radiation
planning,
and
evaluation
oftherapy.
Standard
clinical
imaging
modalities:CT,
MRI,
ultrasound,
limitation
indetection
(
<
0.5
cm),
anddistinguishing
between
benign
andcancerous
tumors.
Molecular
imaging:
Multifunctionalnanoparticles:
MNP,
QDs,
gold
NP,drug
delivery
(siRNA,
DNA,
drug),nanothermotherapy,
photodynamictherapy.(b)
Fluorescencespectraof
mouse
skin
and
QDs
with
UV
excitation.
Due
to
the
largeStokes
shift
of
QDs,
their
fluorescence
signals
can
be
shifted
to
a
spectral
region
where
the
autofluorescence
is
reduced.
See
textfor
further
discussion.Size-tunable
light
emissionPhotostableSimultaneous
excitation
of
QDsLarge
Stokes
shiftFigure
13.
Schematic
illustration
of
a
multifunctional
quantum
dotcoated
with
amphiphilic
polymer.Fig.
14.
Schematic
diagram
showing
the
steps
of
siRNA-QD
in
membrane
binding,
cellular
entry,endosomal
escape,
capturing
by
RNA
binding
proteins,
loading
to
RNA-induced
silencingcomplexes
(RISC),
and
target
degradation.Fig.
16.
Schematic
drawing
of
the
hybrid
structure
of
QD
andamphipol
for
siRNA
delivery
and
real-time
imaging
in
live
cells.Qi
and
Gao,
ACS
nano,
2008,
2(7),
1403–1410,
2008Fig.
17
QD
loading
capacity
and
protection
of
siRNAmoleculesagainst
nuclease
degradation
determined
by
gel
electrophoresis.Qi
and
Gao,
ACS
nano,
2008,
2(7),
1403–1410Fig.
18
Gene
silencing
efficiency
of
siRNA
targeting
Her-2
using
QDPMAL
compared
with
the
classic
transfection
agents,
Lipofectamine
and
PEI.Qi
and
Gao,
ACS
nano,
2008,
2(7),
1403–1410納米分子造影劑產(chǎn)品1)3TP的癌癥診斷技術(shù),基于MRI的診斷乳腺癌、前列腺癌,區(qū)分惡性/良性,〉5mm瘤塊。主要以釓/氧化鐵為組分核磁納米造影劑Palatin技術(shù)公司2007年獲批準(zhǔn)新型造影劑neutrospec,neutrospec含有一個(gè)以锝為標(biāo)記的抗cd15單克隆抗體,可以選擇性的結(jié)合于參與免疫應(yīng)答的嗜中性粒細(xì)胞。neutrospec被注射入血后,可與感染部位存在的嗜中性粒細(xì)胞相結(jié)合,使這些細(xì)胞被放射性示蹤劑所標(biāo)記。Part
III:納米探針Fig.22
Modulating
signaling
pathways
and
probing
biological
interactions
withnanotopographyOligo**?*
?*
*Fig.
25.
Cytotoxicity
of
CNCdetermined
by
detection
ofLDH
release
from
BJ-5acells
cocultured
withextracts
of
CNC
for
72
h.Fig.
26Actin
localization
in
spreading
cells
with
timeControlCNCChitosan3
h3
d11
d3.2納米纖維轉(zhuǎn)染DNAFig.
27.
Human
embryonic
kidney
cell
line
(HEK
293T)
cultured
onSiNWs
(c)
with
and
(d)
without
PEI
treatment
prior
to
GFP
plasmiddeposition.
Yang
et.
al.
J.
AM.
CHEM.
SOC.2007,129,
7228-72293.3靶分子監(jiān)測(cè)納米探針Fig.
28.
Well-dispersed
antibody-nanoshell
conjugates
in
the
absence
of
analytepossess
a
well-defined
extinction
peak
in
the
near-IR.
In
the
presence
of
thecomplementary
analyte,
multiple
nanoshells
bind
to
the
analyte,
causingagglutination
and
acorresponding
reduction
in
the
extinction
peak.Methods
in
Molecular
Biology?
?
303NANOBIOTECHNOLOGYPROTOCOLSFig.
29.
Signal
detection
of
oligonucleotide-derivatized
NBCshybridized
with
complementary
Cy5
oligonucleotide.Methods
in
Molecular
Biology?
?
303NANOBIOTECHNOLOGYPROTOCOLS3.3納米金熒光檢測(cè)核苷酸序列Fig.
30.
Flow
chamber
setup
for
hybridization
and
visualization
of
fluorescence
signaon
the
nanoarray.
Optical
microscope
image
of
an
optical
fiber-bundle
based
nanoarray
containing
individual
300
nmdiameter
fibers;
(ii)
magnified
SEM
image
of
aregion
of
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年度互聯(lián)網(wǎng)金融服務(wù)合同6篇
- 年度水解彈性蛋白產(chǎn)業(yè)分析報(bào)告
- 年度皮膚科醫(yī)院市場(chǎng)分析及競(jìng)爭(zhēng)策略分析報(bào)告
- 2024-2025學(xué)年新教材高中政治第3單元經(jīng)濟(jì)全球化第7課第1框開(kāi)放是當(dāng)代中國(guó)的鮮明標(biāo)識(shí)課時(shí)分層作業(yè)含解析新人教版選擇性必修1
- 何謂二零二五年度合同履行的擔(dān)保專(zhuān)項(xiàng)審計(jì)與報(bào)告合同3篇
- 二零二五版毛竹山承包及竹林農(nóng)業(yè)科技示范合同3篇
- 速寫(xiě)線性課程設(shè)計(jì)
- 2024金融服務(wù)合同范本大全
- 二零二五版餐飲行業(yè)代理招商合同模板
- 2025年度寵物公園門(mén)票銷(xiāo)售與服務(wù)合同范本大全3篇
- 河南省信陽(yáng)市浉河區(qū)9校聯(lián)考2024-2025學(xué)年八年級(jí)上學(xué)期12月月考地理試題(含答案)
- 火災(zāi)安全教育觀后感
- 農(nóng)村自建房屋安全協(xié)議書(shū)
- 快速康復(fù)在骨科護(hù)理中的應(yīng)用
- 國(guó)民經(jīng)濟(jì)行業(yè)分類(lèi)和代碼表(電子版)
- ICU患者外出檢查的護(hù)理
- 公司收購(gòu)設(shè)備合同范例
- 廣東省潮州市2023-2024學(xué)年高二上學(xué)期語(yǔ)文期末考試試卷(含答案)
- 2024年光伏發(fā)電項(xiàng)目EPC總包合同
- 子女放棄房產(chǎn)繼承協(xié)議書(shū)
- 氧化還原反應(yīng)配平專(zhuān)項(xiàng)訓(xùn)練
評(píng)論
0/150
提交評(píng)論